36. Wu et al. (A-38) conducted a study to determine the effect of zidovudine on functional status and well-being in patients with early symptomatic human immunodeficiency virus

(HIV). Thirty-four subjects were assigned at random to placebo and 36 subjects to zidovudine. The mean changes from baseline for zidovudine versus placebo groups were compared. Subjects receiving a placebo reported better quality of life compared to baseline than subjects receiving zidovudine at 24 weeks for all dimensions of well-being, including overall health, energy, mental health, health distress, pain, and quality of life.